Trigeminal Neuralgia - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Trigeminal Neuralgia - Pipeline Review, H2 2016', provides an overview of the Trigeminal Neuralgia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Trigeminal Neuralgia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Trigeminal Neuralgia and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Trigeminal Neuralgia - The report reviews pipeline therapeutics for Trigeminal Neuralgia by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Trigeminal Neuralgia therapeutics and enlists all their major and minor projects - The report assesses Trigeminal Neuralgia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Trigeminal Neuralgia Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Trigeminal Neuralgia - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Trigeminal Neuralgia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Trigeminal Neuralgia Overview 7 Therapeutics Development 8 Pipeline Products for Trigeminal Neuralgia - Overview 8 Pipeline Products for Trigeminal Neuralgia - Comparative Analysis 9 Trigeminal Neuralgia - Therapeutics under Development by Companies 10 Trigeminal Neuralgia - Therapeutics under Investigation by Universities/Institutes 11 Trigeminal Neuralgia - Pipeline Products Glance 12 Clinical Stage Products 12 Early Stage Products 13 Unknown Stage Products 14 Trigeminal Neuralgia - Products under Development by Companies 15 Trigeminal Neuralgia - Products under Investigation by Universities/Institutes 16 Trigeminal Neuralgia - Companies Involved in Therapeutics Development 17 Allergan Plc 17 Biogen Inc 18 KPI Therapeutics, Inc. 19 Merz Pharma GmbH & Co. KgaA 20 Trigemina, Inc. 21 Trigeminal Neuralgia - Therapeutics Assessment 22 Assessment by Monotherapy Products 22 Assessment by Combination Products 23 Assessment by Target 24 Assessment by Mechanism of Action 26 Assessment by Route of Administration 28 Assessment by Molecule Type 30 Drug Profiles 32 (clonidine hydrochloride + naltrexone hydrochloride) - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 incobotulinumtoxin A - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 NeuroRelease TN - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 onabotulinumtoxin A - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 oxytocin - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 raxatrigine hydrochloride - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 Small Molecule to Block TRPV4 and TRPA1 for Pancreatitis and Trigeminal Neuralgia - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 U-2902 - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 Trigeminal Neuralgia - Dormant Projects 51 Trigeminal Neuralgia - Product Development Milestones 52 Featured News & Press Releases 52 Jun 27, 2016: PixarBio Promotes David Kaplan to Chief Commercial Officer, as NeuroRelease a Morphine Strength Non Addictive Pain Treatment Remains on Track for 2018 Launch 52 Mar 30, 2016: PixarBio, the Developers of NeuroRelease A Revolutionary Morphine Strength, Non-Addictive Pain Treatment Appoints Glenn Reiser Vice President of External Affairs 53 Mar 03, 2016: PixarBio's Dr. Taunia Markvicka and Glenn Reiser to Discuss Breakthrough Data on Morphine Strength Non-Addictive Pain Treatment NeuroRelease at the 2016 Congress of Neurological Surgeons Spine Summit held in Orlando, FL March 17-18, 2016 53 Nov 30, 2015: PixarBio's Glenn Reiser to Present Data on NeuroRelease, a Breakthrough Non-opiate and Non-addictive Pain Platform, at the 2015 Life Sciences Summit in New York, NY 54 Oct 26, 2015: PixarBio Announces USFDA OPD Submission of NeuroRelease TN for Orphan Drug Designation for Trigeminal Neuralgia 54 Sep 23, 2014: Convergence Pharmaceuticals' Novel Nav1.7 Selective Sodium Channel Blocker CNV1014802 Demonstrates Proof of Concept in Second Neuropathic Pain Study in Lumbosacral Radiculopathy 55 Jun 16, 2014: Convergence Pharmaceuticals' Novel Sodium Channel Blocker CNV1014802 Shows Excellent Efficacy and Safety in Ground-breaking Phase II Trigeminal Neuralgia Study 55 Jul 30, 2013: Convergence Pharmaceuticals Receives Orphan-Drug Designation for Nav1.7 Blocking Pain Drug CNV1014802 56 Apr 23, 2013: Convergence Pharma Announces Successful Interim Data From Phase II Trigeminal Neuralgia Study 57 Mar 27, 2013: Convergence Pharma Reports Positive Interim Data From Phase II Trigeminal Neuralgia Study Of CNV-1014802 57 Mar 19, 2012: Convergence Initiates Phase II Study For CNV1014802 For Trigeminal Neuralgia 58 Appendix 59 Methodology 59 Coverage 59 Secondary Research 59 Primary Research 59 Expert Panel Validation 59 Contact Us 59 Disclaimer 60
List of Tables
Number of Products under Development for Trigeminal Neuralgia, H2 2016 8 Number of Products under Development for Trigeminal Neuralgia - Comparative Analysis, H2 2016 9 Number of Products under Development by Companies, H2 2016 10 Number of Products under Investigation by Universities/Institutes, H2 2016 11 Comparative Analysis by Clinical Stage Development, H2 2016 12 Comparative Analysis by Early Stage Development, H2 2016 13 Comparative Analysis by Unknown Stage Development, H2 2016 14 Products under Development by Companies, H2 2016 15 Products under Investigation by Universities/Institutes, H2 2016 16 Trigeminal Neuralgia - Pipeline by Allergan Plc, H2 2016 17 Trigeminal Neuralgia - Pipeline by Biogen Inc, H2 2016 18 Trigeminal Neuralgia - Pipeline by KPI Therapeutics, Inc., H2 2016 19 Trigeminal Neuralgia - Pipeline by Merz Pharma GmbH & Co. KgaA, H2 2016 20 Trigeminal Neuralgia - Pipeline by Trigemina, Inc., H2 2016 21 Assessment by Monotherapy Products, H2 2016 22 Assessment by Combination Products, H2 2016 23 Number of Products by Stage and Target, H2 2016 25 Number of Products by Stage and Mechanism of Action, H2 2016 27 Number of Products by Stage and Route of Administration, H2 2016 29 Number of Products by Stage and Molecule Type, H2 2016 31 Trigeminal Neuralgia - Dormant Projects, H2 2016 51
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.